Market Update (NYSE:BMY): U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma

[Business Wire] – Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental Biologics License Application for Opdivo for the treatment of previously . . . → Read More: Market Update (NYSE:BMY): U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma Stock Update (NYSE:BMY): Roche open to alliances in hunt for cancer drug combinations Market Update (NYSE:BMY): Europe pushes back verdict on Bristol immune system cancer drug